About the Authors
- Hideo Yoshida
-
* E-mail: hiyosida@kowa.co.jp
Affiliation Tokyo New Drug Research Laboratories, Kowa Company, Ltd., Tokyo, Japan
- Yuka Ashikawa
-
Affiliation Tokyo New Drug Research Laboratories, Kowa Company, Ltd., Tokyo, Japan
- Shinsuke Itoh
-
Affiliation Tokyo New Drug Research Laboratories, Kowa Company, Ltd., Tokyo, Japan
- Takashi Nakagawa
-
Affiliation Tokyo New Drug Research Laboratories, Kowa Company, Ltd., Tokyo, Japan
- Akimune Asanuma
-
Affiliation Tokyo New Drug Research Laboratories, Kowa Company, Ltd., Tokyo, Japan
- Sohei Tanabe
-
Affiliation Tokyo New Drug Research Laboratories, Kowa Company, Ltd., Tokyo, Japan
- Yoshihiro Inoue
-
Affiliation D. Western Therapeutics Institutes, Inc., Nagoya, Japan
- Hiroyoshi Hidaka
-
Affiliation D. Western Therapeutics Institutes, Inc., Nagoya, Japan
Competing Interests
HY, YA, SI, TN, AA, and ST are employees of Kowa Company, Ltd. YI and HH is an employee and founder of D. Western Therapeutics Institutes, Inc., respectively. Kowa Company has been developing K-134 as a drug for the treatment of intermittent claudication. D. Western therapeutics institutes, Inc. and Kowa Company, Ltd. have a patent associated with K-134 (WO/97/12869). This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: HY YA SI YI HH. Performed the experiments: HY YA SI YI. Analyzed the data: HY YA SI AA ST YI. Wrote the paper: HY SI TN.